Dublin, Dec. 04, 2020 (GLOBE NEWSWIRE) — The “Orphan Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025” report has been added to ResearchAndMarkets.com’s offering.
The global orphan drugs market exhibited moderate growth during 2014-2019. Looking forward, the global orphan drugs market to exhibit moderate growth during the next five years.
Orphan drugs refer to pharmaceutical products used for the diagnosis, prevention and treatment of rare medical disorders. These drugs are manufactured to meet a specific public health requirement and usually have a limited market as they are produced for a small group of patients. They are effective against numerous oncological, metabolic, hematologic, immunologic, infectious and neurological diseases.
Medical ailments, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative and disabling and require specific treatment alternatives that are effective for their particular symptoms.
The increasing prevalence of cancer and other rare genetic disorders is one of the key factors driving the growth of the market. Pharmaceutical manufacturers are developing innovative orphan drugs to provide personalized therapy to patients. The market is also being driven by increasing awareness among the masses regarding the benefits of orphan drugs.
The emergence of new pharmaceutical drug manufacturers and the implementation of favorable government policies to inhibit the spread of contagious diseases are also contributing to the market growth. Additionally, various product innovations, such as the development of biological orphan drugs, are acting as other growth-inducing factors. These drugs can treat diseases, such as cancer, and reverse the damage caused to the stem cells, which is facilitating their overall demand significantly.
Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities, are expected to drive the market further.
Key Questions Answered in This Report:
- How has the global orphan drugs market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global orphan drugs market?
- What are the key regional markets?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the disease type?
- What is the breakup of the market based on the phase?
- What is the breakup of the market based on the top selling drugs?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global orphan drugs market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.4 Market Estimation
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Orphan Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Biological
6.2 Non-Biological
7 Market Breakup by Disease Type
7.1 Oncology
7.2 Hematology
7.3 Neurology
7.4 Cardiovascular
7.5 Others
8 Market Breakup by Phase
8.1 Phase I
8.2 Phase II
8.3 Phase III
8.4 Phase IV
9 Market Breakup by Top Selling Drugs
9.1 Revlimid
9.2 Rituxan
9.3 Copaxone
9.4 Opdivo
9.5 Keytruda
9.6 Imbruvica
9.7 Avonex
9.8 Sensipar
9.9 Soliris
9.10 Others
10 Market Breakup by Distribution Channel
10.1 Hospital Pharmacy
10.2 Retail Pharmacy
10.3 Online Stores
10.4 Others
11 Market Breakup by Region
12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
15 Price Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
- AbbVie Inc.
- Alexion Pharmaceuticals Inc.
- Amgen Inc.
- Biogen Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG (Roche Holding AG)
- Jazz Pharmaceuticals Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/jaiq5n
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
